TWI507416B - 抗ｃｄ４８抗體及其用途 - Google Patents
抗ｃｄ４８抗體及其用途 Download PDFInfo
- Publication number
- TWI507416B TWI507416B TW100134591A TW100134591A TWI507416B TW I507416 B TWI507416 B TW I507416B TW 100134591 A TW100134591 A TW 100134591A TW 100134591 A TW100134591 A TW 100134591A TW I507416 B TWI507416 B TW I507416B
- Authority
- TW
- Taiwan
- Prior art keywords
- antibody
- synthetic
- artificial sequence
- antigen
- prt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38674610P | 2010-09-27 | 2010-09-27 | |
| US201161475280P | 2011-04-14 | 2011-04-14 | |
| US201161515490P | 2011-08-05 | 2011-08-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201305206A TW201305206A (zh) | 2013-02-01 |
| TWI507416B true TWI507416B (zh) | 2015-11-11 |
Family
ID=45870888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW100134591A TWI507416B (zh) | 2010-09-27 | 2011-09-26 | 抗ｃｄ４８抗體及其用途 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9228014B2 (enExample) |
| EP (1) | EP2621952A1 (enExample) |
| JP (2) | JP6096117B2 (enExample) |
| KR (1) | KR20140014067A (enExample) |
| CN (1) | CN103261226B (enExample) |
| AR (1) | AR083044A1 (enExample) |
| AU (1) | AU2011312623B2 (enExample) |
| BR (1) | BR112013007314A2 (enExample) |
| CA (1) | CA2812748A1 (enExample) |
| CL (1) | CL2013000843A1 (enExample) |
| EA (1) | EA030437B1 (enExample) |
| IL (1) | IL225484A (enExample) |
| MX (1) | MX348417B (enExample) |
| MY (1) | MY165273A (enExample) |
| NZ (1) | NZ608660A (enExample) |
| PH (1) | PH12013500564A1 (enExample) |
| SG (1) | SG189089A1 (enExample) |
| TW (1) | TWI507416B (enExample) |
| WO (1) | WO2012047567A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9533039B2 (en) * | 2010-09-27 | 2017-01-03 | Regeneron Pharmaceuticals, Inc. | Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies |
| DK3578201T3 (da) | 2012-06-28 | 2023-05-08 | Univ Of Central Florida Research Foundation Incorporated | Fremgangsmåder og sammensætninger til naturlige dræberceller |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US10435463B2 (en) * | 2014-09-05 | 2019-10-08 | Academisch Medisch Centrum | Hepatitis C virus specific antibody |
| KR20170128256A (ko) * | 2015-03-18 | 2017-11-22 | 시애틀 지네틱스, 인크. | Cd48 항체 및 이의 접합체 |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| JP6805884B2 (ja) | 2017-02-28 | 2020-12-23 | 住友ゴム工業株式会社 | 二輪自動用空気入りタイヤ |
| KR20210084695A (ko) | 2017-07-06 | 2021-07-07 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| US20190194298A1 (en) | 2017-12-22 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| CA3085177A1 (en) | 2018-01-31 | 2019-08-08 | Regeneron Pharamaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| AU2019227531B2 (en) | 2018-02-28 | 2025-01-30 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| US11054389B2 (en) | 2018-03-19 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| WO2020047067A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| JP2022517720A (ja) | 2019-01-16 | 2022-03-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ジスルフィド結合を特徴付けるための方法 |
| JP7541534B2 (ja) | 2019-05-13 | 2024-08-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改善された競合的リガンド結合アッセイ |
| KR20260058863A (ko) | 2019-09-24 | 2026-04-29 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| CA3165060C (en) | 2020-01-21 | 2023-06-20 | Yiming Zhao | Deglycosylation methods for electrophoresis of glycosylated proteins |
| CA3181776A1 (en) * | 2020-05-26 | 2021-12-02 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antibodies |
| KR20230058094A (ko) | 2020-08-31 | 2023-05-02 | 리제너론 파아마슈티컬스, 인크. | 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략 |
| MX2023006010A (es) * | 2020-11-24 | 2023-06-08 | Novartis Ag | Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos. |
| EP4251128A1 (en) | 2020-11-25 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| IL303675A (en) | 2020-12-17 | 2023-08-01 | Regeneron Pharma | Production of protein thermal microgels |
| MX2023008527A (es) | 2021-01-20 | 2023-07-28 | Regeneron Pharma | Metodos para mejorar el valor proteico en cultivo celular. |
| TW202246325A (zh) | 2021-03-03 | 2022-12-01 | 美商再生元醫藥公司 | 用於定量及修飾蛋白質黏度之系統及方法 |
| EP4315344A1 (en) | 2021-03-26 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
| AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| EP4413359A1 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
| EP4413364A2 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| WO2023076340A1 (en) | 2021-10-26 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| EP4493921A1 (en) | 2022-03-18 | 2025-01-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| EP4634659A1 (en) | 2022-12-16 | 2025-10-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20240248097A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| EP4669963A2 (en) | 2023-02-22 | 2025-12-31 | Regeneron Pharmaceuticals, Inc. | SYSTEM FITNESS PARAMETERS AND COLUMN AGING |
| WO2024205282A1 (ko) * | 2023-03-29 | 2024-10-03 | 웰마커바이오 주식회사 | Igsf1 특이적 결합 단백질 및 이의 용도 |
| JP2026514305A (ja) | 2023-05-01 | 2026-05-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | フェノールまたはベンジルアルコールを使用した複数回投与抗体医薬品 |
| US20250086164A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| EP4780828A2 (en) | 2023-09-18 | 2026-07-29 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| CN122138969A (zh) | 2023-10-18 | 2026-06-02 | 瑞泽恩制药公司 | 从过程中上游细胞培养物材料中快速纯化单克隆抗体 |
| AU2024373307A1 (en) | 2023-11-02 | 2026-05-14 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| TW202600593A (zh) | 2024-02-16 | 2026-01-01 | 美商再生元醫藥公司 | 製造濃縮配製包括蛋白質之藥品物質之方法，以及該方法製造之濃縮配製之藥品物質 |
| TW202602489A (zh) | 2024-03-15 | 2026-01-16 | 美商再生元醫藥公司 | 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐 |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
| WO2026060350A1 (en) | 2024-09-13 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods |
| WO2026076201A2 (en) | 2024-10-03 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools |
| WO2026080597A1 (en) | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
| WO2026112457A2 (en) | 2024-11-21 | 2026-05-28 | Regeneron Pharmaceuticals, Inc. | Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof |
| WO2026136650A1 (en) | 2024-12-20 | 2026-06-25 | Regeneron Pharmaceuticals, Inc. | Fixed seed train schedule for improved protein production |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997035614A1 (en) * | 1996-03-27 | 1997-10-02 | Crc For Biopharmaceutical Research Pty. Ltd. | The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias |
| US20070212353A1 (en) * | 2006-02-14 | 2007-09-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Novel therapeutic target and diagnostic marker for asthma and related conditions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4692405A (en) | 1985-03-05 | 1987-09-08 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies to antigen on activated human B-cells and assay therefor, protein antigenic determinant therefor and method of making same |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
| JPWO2005094886A1 (ja) | 2004-03-31 | 2008-02-14 | キリンファーマ株式会社 | Ｇｐｉアンカー蛋白質アゴニストによる調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物 |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| US9097717B2 (en) | 2009-04-10 | 2015-08-04 | Osaka University | Methods of killing myeloma stem and precursor cells by administering anti-CD48 antibodies |
-
2011
- 2011-09-19 AR ARP110103412A patent/AR083044A1/es unknown
- 2011-09-26 TW TW100134591A patent/TWI507416B/zh not_active IP Right Cessation
- 2011-09-26 JP JP2013530383A patent/JP6096117B2/ja not_active Expired - Fee Related
- 2011-09-26 BR BR112013007314A patent/BR112013007314A2/pt active Search and Examination
- 2011-09-26 PH PH1/2013/500564A patent/PH12013500564A1/en unknown
- 2011-09-26 WO PCT/US2011/053193 patent/WO2012047567A1/en not_active Ceased
- 2011-09-26 US US13/244,960 patent/US9228014B2/en active Active
- 2011-09-26 CA CA2812748A patent/CA2812748A1/en active Pending
- 2011-09-26 SG SG2013022173A patent/SG189089A1/en unknown
- 2011-09-26 MX MX2013003468A patent/MX348417B/es active IP Right Grant
- 2011-09-26 MY MYPI2013700476A patent/MY165273A/en unknown
- 2011-09-26 EA EA201370081A patent/EA030437B1/ru not_active IP Right Cessation
- 2011-09-26 AU AU2011312623A patent/AU2011312623B2/en not_active Ceased
- 2011-09-26 EP EP11764071.4A patent/EP2621952A1/en not_active Withdrawn
- 2011-09-26 NZ NZ60866011A patent/NZ608660A/en not_active IP Right Cessation
- 2011-09-26 KR KR1020137008885A patent/KR20140014067A/ko not_active Abandoned
- 2011-09-26 CN CN201180054278.1A patent/CN103261226B/zh not_active Expired - Fee Related
-
2013
- 2013-03-24 IL IL225484A patent/IL225484A/en active IP Right Grant
- 2013-03-27 CL CL2013000843A patent/CL2013000843A1/es unknown
-
2016
- 2016-10-27 JP JP2016210605A patent/JP2017036324A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997035614A1 (en) * | 1996-03-27 | 1997-10-02 | Crc For Biopharmaceutical Research Pty. Ltd. | The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias |
| US20070212353A1 (en) * | 2006-02-14 | 2007-09-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Novel therapeutic target and diagnostic marker for asthma and related conditions |
Non-Patent Citations (1)
| Title |
|---|
| ABADIA-MOLINA AC et al., "CD48 controls T-cell and antigen-presenting cell functions in experimental colitis", Gastroenterology, vol.130, no.2, p.424-434, 2006/02/01 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL225484A (en) | 2017-07-31 |
| MX2013003468A (es) | 2013-05-31 |
| TW201305206A (zh) | 2013-02-01 |
| AU2011312623B2 (en) | 2016-12-15 |
| AU2011312623A1 (en) | 2013-05-02 |
| CA2812748A1 (en) | 2012-04-12 |
| WO2012047567A1 (en) | 2012-04-12 |
| CN103261226A (zh) | 2013-08-21 |
| BR112013007314A2 (pt) | 2017-03-21 |
| EA201370081A1 (ru) | 2013-12-30 |
| EP2621952A1 (en) | 2013-08-07 |
| AR083044A1 (es) | 2013-01-30 |
| JP2013542194A (ja) | 2013-11-21 |
| EA030437B1 (ru) | 2018-08-31 |
| PH12013500564A1 (en) | 2021-06-02 |
| JP6096117B2 (ja) | 2017-03-15 |
| CN103261226B (zh) | 2016-06-15 |
| NZ608660A (en) | 2015-03-27 |
| KR20140014067A (ko) | 2014-02-05 |
| US20120076790A1 (en) | 2012-03-29 |
| IL225484A0 (en) | 2013-06-27 |
| JP2017036324A (ja) | 2017-02-16 |
| MY165273A (en) | 2018-03-20 |
| MX348417B (es) | 2017-06-12 |
| SG189089A1 (en) | 2013-05-31 |
| US9228014B2 (en) | 2016-01-05 |
| CL2013000843A1 (es) | 2014-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6096117B2 (ja) | 抗ｃｄ４８抗体およびその使用 | |
| TWI619729B (zh) | 抗－ｈｌａ－ｂ*２７抗體及其用途 | |
| JP6654165B2 (ja) | 抗ｔｉｅ２抗体およびその使用 | |
| TWI633119B (zh) | 抗－ｉｌ－３３抗體及其用途 | |
| US10513557B2 (en) | Anti-ASIC1 antibodies and uses thereof | |
| JP5701876B2 (ja) | ヒトアンジオポイエチン−２に対する高親和性ヒト抗体 | |
| CA3109513A1 (en) | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof | |
| US9371383B2 (en) | Anti-ASIC1 antibodies and uses thereof | |
| US9533039B2 (en) | Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies | |
| HK40006818B (en) | Anti-asic1 antibodies and uses thereof | |
| HK40006818A (en) | Anti-asic1 antibodies and uses thereof | |
| HK1199269B (en) | Anti-asic1 antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |